Welcome mark muhly | 
 |        

 
Breast Cancer News
Breast Cancer Treatment - National Cancer Institute
www.cancer.gov - 8/12/10
patients who complete treatment for stage I to stage III breast cancer. The frequency of follow-up and the appropriateness ... breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26 (3): 386-91 2008. ...
Considering Metabolic Effects When Making Breast Cancer Treatment Decisions - Cancer Network
www.cancernetwork.com - 8/23/10
cancer events in patients who received an AI as part of adjuvant breast cancer treatment compared with patients treated with 5 ... cancer treatment decisions should involve consideration not only of the risk of breast cancer recurrence but also of competing risks ...
Breast Cancer Prevention - National Cancer Institute
www.cancer.gov - 7/22/10
breast cancer. Among the women who never used HT increased breast cancer risk was associated with weight at entry body ... breast cancer compared with 85 cases in women who received tamoxifen. Noninvasive breast cancers were also reduced with 59 cases ...

Result Pages: 1 2 3 4 5 6 7 8 9 10 Next






 
Patient Resources
Breast Cancer News - Healthcommunities Insider - Oncology Channel
www.oncologychannel.com - 7/6/10
carcinoma in situ (DCIS) may have a new way of determining their chances of developing more invasive tumors down the road. ... treatment because they don't completely understand their risk of developing invasive breast cancer later on. These new understandings from this study ...
Male breast cancer - MayoClinic.com
www.mayoclinic.com - 7/7/10
breast cancer. Doctors know that male breast cancer occurs when some breast cells begin growing abnormally. ... -breast-cancer/DS00661">Male breast cancer</a> Guidelines for sites linking to MayoClinic.com ...
Breast Cancer - Metaplastic: Treatment | Cancer.Net
www.cancer.net - 8/18/10
treatment has not yet been determined. Therefore metaplastic carcinoma of the breast is treated in the same way as a more ... Because it is unknown if metaplastic carcinoma of the breast behaves like the typical infiltrating ductal or lobular cancer ...

Result Pages: 1 2 3 4 5 6 7 8 9 10 Next


 

Order Your Copy!

 


 

 

Breast Cancer

 
Latest Features
August 31, 2010
Breast cancer specialists brace for FDA word on Avastin
An advisory panel recommended revoking bevacizumab’s approval in breast cancer. Oncologists and patients express concern about what the future holds for those who do benefit from bevacizumab. More »
August 24, 2010
Considering Metabolic Effects When Making Breast Cancer Treatment Decisions
Each year in the United States, more than 200,000 women are diagnosed with breast cancer, and 40,000 women die of the disease.[1] Approximately two-thirds of breast cancers are hormone receptor–positive, and medications that suppress estrogen are the cornerstone of adjuvant therapy for these tumors.... More »
August 17, 2010
State breast cancer screening programs nationwide face cuts
States across the country are reducing funding for their breast cancer screening programs or tightening eligibility requirements, leaving many women without their annual screening mammograms. In all, 17 states have cut back on the programs to help balance their budgets. More »
August 10, 2010
FDA panel says no more Avastin in breast cancer
An FDA advisory panel has recommended that bevacizumab (Avastin) no longer be approved for use in patients with breast cancer. More »
August 10, 2010
Cell-signaling pathway may be new Rx target ER+ breast cancer
Cancer investigators at Vanderbilt-Ingram Cancer Center in Nashville, Tenn., have confirmed that the PI3-kinase (PI3K) pathway offers a promising therapeutic target in patients who develop resistance to standard endrocine therapies. More »
July 22, 2010
2010 – Focus on Breast Cancer
Advances in our understanding of the underlying molecular mechanisms in the development of breast cancer have been at the forefront of recent clinical research. Many of the ASCO 2010’s hottest sessions featured clinical trials that looked at combination therapies with targeted agents as well as... More »
July 13, 2010
Eribulin amplifies survival in pretreated metastatic breast cancer patients
If approved, oncologists will have a new therapeutic option with proven benefits, acceptable toxicity, said EMBRACE trial leader. More »
July 13, 2010
Radiation after mastectomy improves overall survival in invasive breast cancer
Postmastectomy radiation therapy increased five-year overall survival by almost 50% and reduced recurrence risk by nearly 30%, according to a study in the International Journal of Radiation Oncology, Biology, Physics. More »
June 25, 2010
ASCO 2010―Focus on Breast Cancer
Advances in our understanding of the underlying molecular mechanisms in the development of breast cancer have been at the forefront of recent clinical research. Many of the ASCO 2010’s hottest sessions featured clinical trials that looked at combination therapies with targeted agents as well as... More »
June 22, 2010
Studies strengthen connection between mammographic breast density and a woman’s risk of breast cancer
Modifiable-risk biomarkers are increasingly being used in early-phase research to guide larger prevention trials. More »
Showing 1 - 10 of 1,014 results.
Page of 102
First Previous Last
 
Clinical Trials
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov - 8/25/10
Primary To determine the rate of complete tumor ablation in patients with invasive ductal breast carcinoma treated with cryoablation. Secondary To evaluate the negative predictive value of MRI in the post-ablation setting in detecting residual in situ or invasive breast carcinoma. ...
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer - Full Tex
www.clinicaltrials.gov - 8/23/10
mastectomy with margins negative* for invasive disease and ductal carcinoma in situ) with planned radiotherapy NOTE: *If all other ... treated basal cell or squamous cell skin cancer nonbreast carcinoma in situ contralateral or ipsilateral carcinoma in situ of the breast ...
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov - 8/8/10
Identify a panel of methylated gene markers in serum from women with metastatic breast cancer that is significantly different from that observed in healthy participants. ... breast cancer patients and women without a history of breast cancer (ie healthy women or "normals') ...

Result Pages: 1 2 3 4 5 6 7 8 9 10 Next





 
Conference Reports

Miami Breast Cancer Conference

In our exclusive on-site coverage of this event, ONCOLOGY has engaged nationally recognized breast cancer specialist Harold J. Burstein, MD, PhD, Associate Professor of Medicine, Harvard Medical School to provide insight on the meeting’s most clinically relevant sessions.

 

Our coverage will also include expert perspectives, abstract/poster reviews, and interviews and podcasts with other leaders in the field.

 

 

Advances in HER2-positive breast cancer:  An interview with Eric P. Winer, MD
Oncology,  March 2010

 

Podcast: The role of maintenance therapy for metastatic breast cancer
Oncology,  March 2009